Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis".

Attauabi, Mohamed; Seidelin, Jakob Benedict; Burisch, Johan

Attauabi, Mohamed; Seidelin, Jakob Benedict; Burisch, Johan.

Afiliação

Attauabi M; Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Children, adolescents and adults, University of Copenhagen, Hvidovre Hospital, Denmark; Department of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Denmark. Electronic address: Mohamed.Attauabi.01@regionh.dk.
Seidelin JB; Department of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Denmark.
Burisch J; Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Denmark; Copenhagen Center for Inflammatory Bowel Disease in Children, adolescents and adults, University of Copenhagen, Hvidovre Hospital, Denmark.

Dig Liver Dis ; 55(2): 300-301, 2023 02.

Article em En | MEDLINE | ID: mdl-36464612

Assuntos

Colite Ulcerativa; Doença de Crohn; Humanos; Colite Ulcerativa/tratamento farmacológico; Doença de Crohn/tratamento farmacológico; Anticorpos Monoclonais Humanizados/uso terapêutico; Fármacos Gastrointestinais/uso terapêutico; Terapia Biológica

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Colite Ulcerativa / Doença de Crohn Tipo de estudo: Systematic_reviews Idioma: En Revista: Dig Liver Dis Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google